<DOC>
	<DOC>NCT00600873</DOC>
	<brief_summary>R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.</brief_summary>
	<brief_title>R(+)PPX High Dose Treatment of ALS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>definite ALS no prior exposure to R(+)PPX ALSFRS at baseline &lt;40 FVC at baseline &lt;70%</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>neuroprotection</keyword>
	<keyword>oxidative stress</keyword>
</DOC>